Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Regulatory Routine +

MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling

US Rescheduling Confirmed, But Canadian Revenue Headwinds Loom

By The Northwire Desk — AI Analysis Apr 27, 2026 · 08:30 LABS · 0.065 MEDIPHARM LABS CORP. J
Executive Summary
  • The U.S. Department of Justice and DEA final order rescheduling cannabis from Schedule I to Schedule III took effect on April 22, 2026.
  • MediPharm Labs confirms operational readiness with existing FDA site registration and Health Canada Drug Establishment License (DEL).
  • Company highlights track record supplying over 10 active clinical trials including NIH-funded studies.
  • Regulatory shift expected to remove "Schedule I trafficking" restrictions for institutional investors, potentially increasing capital inflow.
  • This news validates the December 2025 Executive Order announcement and confirms the implementation timeline.
Material Impact
  • The regulatory change is material in principle but largely priced in following the December 2025 announcement.
  • Confirmation of effective date removes uncertainty regarding Section 280E tax implications for U.S. research partners.
  • No new revenue contracts or specific U.S. sales figures disclosed in this release, limiting immediate financial impact.
  • The news reinforces the company's pharmaceutical positioning but does not alter the fundamental risk profile regarding domestic Canadian revenue cuts.
  • Market reaction has been muted (price stagnation), suggesting investors view this as expected execution rather than a new catalyst.
LABS · Price
Company Overview
  • MediPharm Labs operates across four verticals: International Medical Cannabis, Canadian Medical Cannabis, Pharmaceutical/B2B, and Adult-Use/Wellness.
  • Flagship Project: GMP-certified production facilities in Canada (Napanee) with EU-GMP compliance and FDA-inspected status.
  • Key Assets: Two owned production facilities valued at >$15M; Health Canada Drug Establishment License (DEL).
  • Global Footprint: Supplies medical cannabis to Germany, UK, Australia, France, Brazil, and New Zealand.
  • Clinical Focus: Active participation in over 10 U.S. clinical trials including NIH-funded studies.
Read the original news release →

More from MEDIPHARM LABS CORP. J

May 28, 2026 · 08:00

MediPharm Labs Turns EBITDA Positive Amidst Revenue Contraction and Governance Shifts

Regulatory May 13, 2026 · 07:30

MediPharm Labs scrapes to adjusted EBITDA profitability in Q1 2026, but a veteran affairs reimbursement cut looms large over its direct-to-patient business.

Earnings Mar 30, 2026 · 07:45

MediPharm Posts Margin Recovery and Steady International Growth, Yet Profitability Remains Elusive

Earnings Mar 25, 2026 · 19:05

MediPharm Delivers Margin Recovery and Near-Breakeven EBITDA as International Sales Offset Domestic Stagnation

Earnings Jan 19, 2026 · 08:00

MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO

Management Jan 13, 2026 · 18:47

Medipharm Labs signs Costa Rica supply agreement

M&A / Property